Catalent Inc. (CTLT)
| Bid | n/a |
| Market Cap | 11.52B |
| Revenue (ttm) | 4.42B |
| Net Income (ttm) | -413M |
| EPS (ttm) | -2.28 |
| PE Ratio (ttm) | -27.842105263157894 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | n/a |
| Volume | 13,674,041 |
| Avg. Volume (20D) | 2,268,467 |
| Open | 63.49 |
| Previous Close | 63.48 |
| Day's Range | 63.44 - 63.50 |
| 52-Week Range | 42.11 - 63.50 |
| Beta | 1.16 |
About CTLT
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use...
Analyst Forecast
According to 4 analyst ratings, the average rating for CTLT stock is "Hold." The 12-month stock price forecast is $63.5, which is an increase of 0.03% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
5 days ago · proactiveinvestors.com
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMILisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration with Catalent. The company told investors tha...
